3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
5
Thyroid Neoplasms
1
Patient Acceptance of Health Care
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
lenvatinib
3
cabozantinib
2
Thyrotropin Alfa
2
vandetanib
1
trametinib
1
sintilimab
1
selpercatinib
1
pralsetinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
larotrectinib
1
dabrafenib
1
anlotinib
1
acetaminophen, codeine drug combination
1
Tramadol
1
Thyroxine
1
Technetium Tc 99m Sestamibi
1
Sunitinib
1
Sodium Chloride
1
Ondansetron
1
Negative-Pressure Wound Therapy
1
Indocyanine Green
1
Fentanyl
1
Conversion to Open Surgery
1
Capsules
1
Aprepitant
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Thyroid Neoplasms
×
palbociclib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled